UPDATED Jun 27, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$909.04 | 2.6% | 95.7% | US$811.5b | US$860.55 | PE133.3x | E27.2% | 0.6% | Pharmaceuticals & Biotech | ||
UNH | US$486.44 | 0.4% | 2.1% | US$445.5b | US$575.77 | PE29.1x | E19.7% | 1.7% | Healthcare | ||
JNJ | US$145.80 | -1.3% | -11.2% | US$353.3b | US$171.72 | PE20.6x | S4.5% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$129.82 | 0.1% | 14.3% | US$333.1b | US$142.68 | PE142.6x | E23.7% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$168.99 | -1.8% | 26.8% | US$302.2b | US$183.24 | PE50.1x | E21.9% | 3.7% | Pharmaceuticals & Biotech | ||
AZN | UK£123.28 | -0.6% | 9.7% | UK£191.1b | UK£137.44 | PE38.2x | E15.6% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$550.78 | -1.2% | 7.1% | US$213.1b | US$628.80 | PE34.8x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
DHR | US$251.76 | 1.3% | 5.9% | US$187.8b | US$273.31 | PE45.8x | E13.7% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$104.65 | -1.8% | -2.8% | US$182.5b | US$125.16 | PE32.5x | E11.3% | 2.1% | Healthcare | ||
AMGN | US$313.69 | 1.2% | 41.8% | US$167.8b | US$316.44 | PE44.7x | E18.2% | 2.9% | Pharmaceuticals & Biotech | ||
ISRG | US$445.11 | 2.9% | 31.5% | US$157.0b | US$426.49 | PE79.4x | E11.7% | n/a | Healthcare | ||
PFE | US$27.80 | 0.2% | -23.0% | US$155.4b | US$31.92 | PS2.9x | E30.6% | 6.0% | Pharmaceuticals & Biotech | ||
SYK | US$340.54 | -0.2% | 12.8% | US$129.7b | US$372.94 | PE38.6x | E10.5% | 0.9% | Healthcare | ||
ELV | US$535.77 | 0.2% | 21.7% | US$124.2b | US$608.98 | PE19.9x | E12.1% | 1.2% | Healthcare | ||
VRTX | US$472.51 | 0.2% | 35.7% | US$122.3b | US$468.27 | PE30.3x | E10.4% | n/a | Pharmaceuticals & Biotech | ||
REGN | US$1,050.86 | 0.6% | 48.3% | US$115.3b | US$1,051.47 | PE29.4x | E12.3% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$77.00 | 0% | 44.5% | US$113.4b | US$82.35 | PE64.1x | E18.1% | n/a | Healthcare | ||
MDT | US$79.33 | -1.0% | -8.6% | US$102.6b | US$94.03 | PE27.7x | E12.8% | 3.5% | Healthcare | ||
CI | US$334.15 | -1.1% | 20.5% | US$95.9b | US$392.79 | PE26.2x | E18.6% | 1.7% | Healthcare | ||
CSL | AU$295.16 | 0.7% | 6.4% | AU$142.6b | AU$307.57 | PE38.2x | E14.7% | 1.2% | Pharmaceuticals & Biotech | ||
HCA | US$343.29 | 1.5% | 14.3% | US$89.2b | US$351.29 | PE16.4x | E6.0% | 0.8% | Healthcare | ||
GILD | US$68.83 | 0.5% | -9.4% | US$86.4b | US$82.97 | PE176.8x | E36.2% | 4.5% | Pharmaceuticals & Biotech | ||
BMY | US$41.51 | 1.1% | -35.1% | US$86.2b | US$53.19 | PS1.8x | E44.7% | 5.8% | Pharmaceuticals & Biotech | ||
GSK | UK£15.26 | -5.7% | 9.5% | UK£62.2b | UK£20.28 | PE13.9x | E11.8% | 3.8% | Pharmaceuticals & Biotech |